LENZ Company Profile and Key Details

LENZ Therapeutics, Inc. (NASDAQ:LENZ) closed at $11.72 USD, losing -$0.78 (-6.24%) from the previous close of $12.50. The stock is currently within 5% of its 52-week low $11.21 and $50.40. With a market capitalization of about $366.72 million, LENZ Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.51). Key stats such as the average daily volume over the past year has been around 942.21 thousand shares, in line with its 52-week average. Headquartered in Solana Beach, CA, LENZ Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Evert Schimmelpennink, the company employs approximately 6 people and listed since March 22, 2024. LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.

LENZ has shown mixed momentum, gaining 24.47% over the past week and -49.35% over the past quarter, though year-to-date performance is up 21.12%. Short-term trend indicators are bullishly aligned (SMA20 -2.09%, SMA50 -15.53%, SMA200 -53.47%). The stock’s 14-day RSI is 41.91 (neutral), while the ATR of 1.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.17% below its high and over 17.77% above its low. Average 10-day trading volume of 713.96 thousand shares is below the 3-month average of 914.91 thousand, indicating normal recent market interest.

LENZ Therapeutics, Inc. last paid a dividend of 7.21 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.88. This means the shares are trading above this model’s fair value.

LENZ Therapeutics, Inc. generated EPS of -$2.11 over the past year. Five-year average earnings growth is -181.63%. Wall Street analysts project EPS growth of 30.84% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $67.00 to $40.00. The high target offers 471.67% upside. The low target suggests 241.3% downside. The mean target is $51.12. This offers 336.18% upside. LENZ Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 05, 2025, missed forecasts by -11.94%. The prior quarter beat by -8.62%. Over the last six quarters, Apple has recorded several small beats. These include -18.37% in August 14, 2024.

LENZ Therapeutics, Inc. has 28.52 million shares outstanding. The public float is 13.13 million shares, elevated short interest at 24.82% of float. This equals 3.82 million shares. The short ratio is 14.15 days. Institutional investors hold 102.6% of the float. Insiders own 2.73%. Versant Venture Capital VI, L.P. holds 764.13 thousand shares, RA CAPITAL MANAGEMENT, L.P. has 694.76 thousand shares and MCCOLLUM JAMES W has 10.50 thousand shares. Over the past six months, insider transactions show net selling. They sold 6.04 thousand shares across 3 transactions.